NCT02111707

Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 534 (actual)
• Sponsor: University of Alberta · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To determine if the timing of administration of indomethacin affects the primary outcome of post-ERCP pancreatitis (PEP). Patients undergoing ERCP will be randomly assigned to receive pre or post-procedure rectal indomethacin to prevent the occurrence of PEP.

Conditions

• Acute Pancreatitis

Interventions

Type	Name	Description
DRUG	Rectal indomethacin 100mg one time before or after ERCP	Patients will receive rectal indomethacin suppository 30 minutes before or immediately after ERCP for prevention of post-procedure pancreatitis. Patients will be randomized to the timing of administration.

Timeline

• Start date: 2014-04-01
• Primary completion: 2017-09-01
• Completion: 2017-09-01
• First posted: 2014-04-11
• Last updated: 2017-10-25

Locations

1 site across 1 country: Canada